

PRESS RELEASE

For Immediate Release

Human Metabolome Technologies, Inc., (HMT) expands to U.S., opening office in Cambridge, Mass.

Proximity to world-class institutions and pharmaceutical companies for cancer and biomarker research makes Cambridge the top choice for HMT

Cambridge, Mass. - November 9, 2012 - [Human Metabolome Technologies, Inc.](http://www.hmt.com) (HMT), the leading developer of capillary electrophoresis mass spectrometry (CE-MS) based metabolomics, today announced the opening of its first U.S. office in Cambridge, Mass. The new office is expected to house up to 20 employees and a laboratory by 2015. HMT is based in Tsuruoka, Japan.

“Cambridge provides the perfect combination of academic and industrial arenas especially associated with the field of life sciences, food engineering and environmental studies,” said Tsutomu (Tom) Hoshiba, President, HMT America. “HMT provides cutting-edge solutions to life scientists, medical doctors and pharmacologists via our state-of-the-art metabolomics technology based on capillary electrophoresis mass spectrometry (CE-MS), and we believe that Cambridge is the place to be for networking with businesses that will make the most of our solutions.”

The location of the office was based largely on accessibility for globally competitive pharmaceutical companies and research institutions to HMT’s most important metabolome analysis services, CARCINOSCOPE, which was specifically designed for cancer research, and BASIC SCAN for more global, general-purpose metabolomics research, including biomarker discovery and companion diagnostics.

“Thanks to our growth strategy of investing in education, innovation and infrastructure, Massachusetts continues to lead the world in life sciences,” said Governor Deval Patrick. “We welcome HMT to Massachusetts and look forward to working with them to create jobs and opportunities in the Commonwealth.”

“We welcome HMT to Massachusetts,” said Ken Brown, Executive Director of the Massachusetts Office of International Trade & Investment. “HMT will join a growing roster of life sciences companies from Asia in the Commonwealth and we wish them success.”

“On behalf of the Center, I would like to extend our warmest congratulations to the team at HMT as they open their first U.S. office here in Massachusetts,” said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center, the agency charged with implementing Governor Patrick’s 10-year, \$1 billion Life Sciences Initiative. “Massachusetts is a global leader in cancer drug development, and HMT will be an important new addition to our oncology community. We are very excited that HMT has chosen to build its metabolomics technology business here.”

“HMT’s decision to grow in Massachusetts highlights the strength of the cluster here in the Commonwealth and speaks to our leadership position in the most cutting-edge oncology research,” said Robert K. Coughlin, President & CEO of MassBio, a 600+ member life sciences trade association. “We’re thrilled to have a growing, global company like HMT build a presence here in the Commonwealth and look forward to working with Tom and his team.”

With its headquarters and laboratory in Tsuruoka, Japan, HMT has been the leading metabolome analysis provider for nine years domestically. HMT also has two sales offices and 50 employees total in Japan.

The new U.S. office is based at:

Human Metabolome Technologies America
1 Kendall Square
Cambridge, MA 021139
USA

About Human Metabolome Technologies, Inc.

Human Metabolome Technologies, Inc. (HMT) is a Japan-based biotechnology company providing capillary electrophoresis mass spectrometry based metabolomics services. HMT's primary business aims to provide complete solutions for metabolomics research in biomarker discovery, drug design, diagnostic technology and food production.

HMT was founded in July 2003 by Professor Masaru Tomita, Ph.D., Director of the Institute for Advanced Biosciences (IAB), Keio University, Japan, and by IAB's Professor Tomoyoshi Soga, Ph.D. The company has been awarded government funding from the New Energy and Industrial Technology Development Organization. HMT has also established a number of partnerships, including Agilent Technologies, Inc., Mizkan Group Corporation, Ajinomoto Co., Inc., and Mitsubishi Pharma Corporation in Japan.

HMT America contact:

Tsutotmu Hoshiba
hoshiba@humanmetabolome.com
617-871-9940

###